Questionable summaries of questionable evidence

Comment

Tom A Yates. QJM. 2012 Mar.

. 2012 Mar;105(3):294-5; discussion 295; author reply 295-6.

doi: 10.1093/qjmed/hcr246. Epub 2011 Dec 30.

No abstract available

Comment on

Challenges of stroke prevention in patients with atrial fibrillation in clinical practice.
Hobbs FD, Leach I. Hobbs FD, et al. QJM. 2011 Sep;104(9):739-46. doi: 10.1093/qjmed/hcr092. Epub 2011 Jul 12. QJM. 2011. PMID: 21750020 Review.
Update on anti-coagulation in atrial fibrillation.
Kreuzer J. Kreuzer J. QJM. 2011 Sep;104(9):747-60. doi: 10.1093/qjmed/hcr107. Epub 2011 Aug 3. QJM. 2011. PMID: 21816811 Free PMC article. Review.

[New oral anticoagulants for the prevention of stroke in patients with non-valvular atrial fibrillation].
Bosch M, Llop R, Lalueza P, Villar Mdel M. Bosch M, et al. Med Clin (Barc). 2013 Mar 2;140(5):229-31. doi: 10.1016/j.medcli.2012.10.015. Epub 2012 Dec 29. Med Clin (Barc). 2013. PMID: 23276615 Spanish. No abstract available.
Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.
Katsnelson M, Sacco RL, Moscucci M. Katsnelson M, et al. Stroke. 2012 Apr;43(4):1179-85. doi: 10.1161/STROKEAHA.111.639864. Stroke. 2012. PMID: 22454426 Review. No abstract available.
Atrial fibrillation, stroke and anticoagulation.
Roy D, Mukherjee S, Chakravarty A. Roy D, et al. J Assoc Physicians India. 2002 Sep;50:1153-8. J Assoc Physicians India. 2002. PMID: 12516699 Review. No abstract available.
[Atrial fibrillation: Thromboembolic risk factor or marker? From concept to therapy].
Le Heuzey JY. Le Heuzey JY. Presse Med. 2017 Jul-Aug;46(7-8 Pt 1):751-757. doi: 10.1016/j.lpm.2017.06.013. Epub 2017 Jul 27. Presse Med. 2017. PMID: 28757174 French.
Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
Rajappan K. Rajappan K. Heart. 2013 Mar;99(6):361-2. doi: 10.1136/heartjnl-2012-302762. Epub 2012 Sep 28. Heart. 2013. PMID: 23024007 No abstract available.